Related Experiment Video
Updated: Mar 15, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.9K
Immunobiology and immunotherapy in genitourinary malignancies
Marinos Tsiatas1, Petros Grivas2
1Department of Genitourinary Oncology, Athens Medical Center, Maroussi, Greece ;
Annals of Translational Medicine
|August 27, 2016
Summary
Immunotherapy, including checkpoint inhibitors, offers significant survival benefits for genitourinary cancers like advanced renal cell carcinoma and urothelial carcinoma. Ongoing research explores novel combinations to further enhance treatment efficacy and patient outcomes.
Area of Science:
- Oncology
- Immunology
- Genitourinary Cancers
Background:
- Immunotherapy is a cornerstone in treating genitourinary (GU) cancers, with established roles for interleukin-2 (IL-2) in renal cell carcinoma (RCC) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer (NMIBC).
- The approval of sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC) and nivolumab (anti-PD-1) for advanced RCC marked significant advancements.
Purpose of the Study:
- To review the current landscape and future directions of immunotherapy in genitourinary cancers.
- To highlight recent clinical trial successes and ongoing research into novel therapeutic combinations.
Main Methods:
- Review of recent clinical trials and FDA approvals for immunotherapies in GU cancers.
- Discussion of ongoing research into combination therapies and biomarker discovery.
Main Results:
- Immune checkpoint inhibitors have demonstrated significant clinical benefits, including durable responses and improved overall survival (OS) in advanced RCC and urothelial carcinoma (UC).
- Atezolizumab recently gained FDA approval for platinum-treated advanced UC, underscoring the growing efficacy of these agents.
- Numerous trials are investigating combinations of immune checkpoint inhibitors with chemotherapy, vaccines, targeted therapies, and other agents.
Conclusions:
- Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized GU cancer treatment, offering meaningful clinical benefits and improved safety profiles.
- Further research focusing on understanding antitumor immune responses, biomarker validation, rational trial design, and stakeholder collaboration is crucial to maximize the potential of immunotherapy in GU oncology.
Related Concept Videos
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:21Nursing Assessment of the Genitourinary System I: Health History
536
The genitourinary system is critical to maintaining fluid balance, waste elimination, and reproductive function. Nurses play a vital role in assessing this system, beginning with a thorough health history. This process involves gathering patient information, identifying risk factors, and recognizing symptoms of genitourinary disorders. Early detection is vital for timely interventions and management.1. Gathering Patient InformationA complete health history includes the patient’s personal,...
536
01:30Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K